Weiss Ratings reissued their sell (e+) rating on shares of 111 (NASDAQ:YI - Free Report) in a research note issued to investors on Friday,Weiss Ratings reports.
111 Stock Performance
Shares of NASDAQ YI traded down $0.05 during midday trading on Friday, hitting $8.66. 19,017 shares of the company's stock traded hands, compared to its average volume of 20,771. 111 has a 1 year low of $4.15 and a 1 year high of $15.80. The stock has a market capitalization of $74.06 million, a price-to-earnings ratio of -2.17 and a beta of 0.45. The firm has a fifty day moving average of $6.57 and a 200 day moving average of $7.28.
Institutional Trading of 111
A number of hedge funds and other institutional investors have recently modified their holdings of the company. FIL Ltd bought a new position in 111 in the 4th quarter worth $450,000. Napean Trading & Investment Co Singapore PTE Ltd bought a new position in shares of 111 in the fourth quarter worth about $245,000. Finally, JPMorgan Chase & Co. grew its position in shares of 111 by 43,619.9% during the fourth quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company's stock worth $191,000 after purchasing an additional 305,339 shares in the last quarter. 21.32% of the stock is owned by hedge funds and other institutional investors.
111 Company Profile
(
Get Free Report)
111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.
Recommended Stories
Before you consider 111, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 111 wasn't on the list.
While 111 currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
